Literature DB >> 11206966

Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy.

M J Treadwell1, L Weissman.   

Abstract

We designed a study to obtain follow-up on behavioral aspects of compliance with home deferoxamine administration, explore social factors that might influence compliance, and evaluate the effectiveness of a pilot intervention program for patients with thalassemia or sickle cell disease who were receiving chronic transfusion therapy. Thirty-one patients between the ages of 6 and 21 years and their primary caregivers were administered a 24-hour recall Interview about home care. Fifteen went on to participate in a Desferal Day Camp, which combined educational strategies with peer support. Behavioral measures of treatment adherence were similar for most patients with sickle cell disease and thalassemia. Patient compliance with days of deferoxamine administration at follow-up was associated with initial compliance, perceived support, and patient and caregiver knowledge. Increased sharing of responsibilities for home care by patients and caregivers and caregiver knowledge were associated with lower ferritin and liver iron levels. A subsample of 3 patients who were extremely noncompliant with days of deferoxamine administration was examined separately; these patients were found to be moderately compliant with the number of hours and amount of deferoxamine administered and to share fewer home care tasks with primary caregivers. Participation in Desferal Day Camp did not result in increases in knowledge or peer support, suggesting that future interventions should focus on family support and on improving self-regulatory skills. The crucial role of collaboration among patients, families, and health care providers in developing interventions to enhance adherence was emphasized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206966     DOI: 10.1016/s0037-1963(01)90064-2

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  11 in total

1.  Adherence to hydroxyurea therapy in children with sickle cell anemia.

Authors:  Courtney D Thornburg; Agustin Calatroni; Marilyn Telen; Alex R Kemper
Journal:  J Pediatr       Date:  2009-11-01       Impact factor: 4.406

2.  Disease management, coping, and functional disability in pediatric sickle cell disease.

Authors:  Gloria Oliver-Carpenter; Ilana Barach; Lori E Crosby; Jessica Valenzuela; Monica J Mitchell
Journal:  J Natl Med Assoc       Date:  2011-02       Impact factor: 1.798

Review 3.  Psychological therapies for thalassaemia.

Authors:  Kofi A Anie; Pia Massaglia
Journal:  Cochrane Database Syst Rev       Date:  2014-03-06

Review 4.  Medication adherence among pediatric patients with sickle cell disease: a systematic review.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Patricia L Kavanagh; Lori E Crosby; Chris Malone; Katie Lobner; David G Bundy
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

Review 5.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Authors:  Sherif M Badawy; Kerry Morrone; Alexis Thompson; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

Review 7.  Drug compliance in adolescents: assessing and managing modifiable risk factors.

Authors:  Betty Staples; Terrill Bravender
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings.

Authors:  Jeffrey I Gold; Nicole E Mahrer; Marsha Treadwell; Lina Weissman; Elliott Vichinsky
Journal:  J Behav Med       Date:  2008-09-11

9.  Negative affect differentiation and adherence during treatment for thalassemia.

Authors:  Karin G Coifman; Gail S Ross; Dorothy Kleinert; Patricia Giardina
Journal:  Int J Behav Med       Date:  2014-02

Review 10.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.